Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
0.7445
-0.0627 (-7.77%)
At close: May 4, 2026, 4:00 PM EDT
0.7599
+0.0154 (2.07%)
After-hours: May 4, 2026, 7:44 PM EDT
Vivos Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Vivos Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $2.75, which forecasts a 269.38% increase in the stock price over the next year. The lowest target is $2.50 and the highest is $3.00.
Price Target: $2.75 (+269.38%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vivos Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $5.5 → $3 | Strong Buy | Maintains | $5.5 → $3 | +302.96% | Apr 22, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $2.5 | Strong Buy | Maintains | $7 → $2.5 | +235.80% | Apr 17, 2026 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $6.5 → $5.5 | Strong Buy | Maintains | $6.5 → $5.5 | +638.75% | Dec 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +840.23% | Nov 17, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $6.2 → $6.5 | Strong Buy | Maintains | $6.2 → $6.5 | +773.07% | Sep 9, 2025 |
Financial Forecast
Revenue This Year
29.59M
from 17.44M
Increased by 69.66%
Revenue Next Year
43.91M
from 29.59M
Increased by 48.38%
EPS This Year
-1.28
from -2.06
EPS Next Year
-0.36
from -1.28
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 33.1M | 54.8M |
| Avg | 29.6M | 43.9M |
| Low | 22.5M | 33.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | 89.6% | 85.0% |
| Avg | 69.7% | 48.4% |
| Low | 29.2% | 12.4% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -0.89 | -0.37 |
| Avg | -1.28 | -0.36 |
| Low | -1.68 | -0.34 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.